BRAF V600E MUTATION POSITIVE
Clinical trials for BRAF V600E MUTATION POSITIVE explained in plain language.
Never miss a new study
Get alerted when new BRAF V600E MUTATION POSITIVE trials appear
Sign up with your email to follow new studies for BRAF V600E MUTATION POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail may reboot radioiodine in resistant thyroid cancers
Disease control CompletedThis early-phase trial tested whether combining two drugs, vemurafenib and copanlisib, can help radioactive iodine therapy shrink tumors in people with advanced thyroid cancer that no longer responds to standard radioiodine treatment. Only 8 participants with a specific BRAF gene…
Matched conditions: BRAF V600E MUTATION POSITIVE
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Real-world data sheds light on tough-to-treat colon cancer
Knowledge-focused CompletedThis study looked back at medical records of 274 people with a specific type of advanced colon cancer (BRAF V600E mutation) to see which treatments doctors used first and how well they worked. Since there is no standard targeted therapy for this cancer, the goal was to understand…
Matched conditions: BRAF V600E MUTATION POSITIVE
Sponsor: Pierre Fabre Medicament • Aim: Knowledge-focused
Last updated May 17, 2026 01:44 UTC